Clorox expects August's cybersecurity attack to have a 'material' impact on first-quarter results
Shares of Clorox Co. (CLX) dropped 2.2% toward a 7 1/2-month low in premarket trading Monday, after the cleaning and household products said a cybersecurity attack identified last month (Aug. 14) will have a "material" impact on fiscal first-quarter results. "Clorox is still evaluating the extent of the financial and business impact," Clorox said in a statement. "It is premature for the Company to determine longer-term impact, including fiscal year outlook, given the ongoing recovery," Clorox added. The company said it is operating at a lower rate of order processing, as the attack damaged parts of its information-technology infrastructure, causing "widescale disruption" of its operations. Clorox expects automated order processing to return to normal during the week of Sept. 25, and expects the ramp up to full production to occur over time. The stock, which is on track to open at the lowest price seen since Feb. 2, has dropped 6.6% over the past three months through Friday, while the S&P 500 has gained 0.9%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-18-23 0632ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks